ABBREVIATIONS AE = adverse event; BDI = Beck Depression Inventory; CDRS = Clinical Dyskinesia Rating Scale; DBS = deep brain stimulation; GPi = globus pallidus pars interna; GRADE = Grading of Recommendations Assessment, Development and Evaluation; IQR = interquartile range; LED = levodopa-equivalent dose; PD = Parkinson's disease; RCT = randomized controlled trial; RR = risk ratio; SE = standard error; STN = subthalamic nucleus; UPDRS = United Parkinson's Disease Rating Scale; WMD = weighted mean difference. Screens were conducted independently and in duplicate. Among the 623 studies initially identified (615 through database search, 7 through manual review of bibliographies, and 1 through a repeat screen of literature prior to submission), 19 underwent full-text review; 13 of these were included in the quantitative meta-analysis. Data were extracted independently and in duplicate. The Cochrane Collaboration tool was used to assess the risk of bias. The GRADE evidence profile tool was used to assess the quality of the evidence. Motor scores, medication dosage reduction, activities of daily living, depression, dyskinesias, and adverse events were compared. The influence of disease duration (a priori) and the proportion of male patients within a study (post hoc) were explored as potential subgroups. RESULTS Thirteen studies (6 original cohorts) were identified. 
I n patients with advanced Parkinson's disease (PD), deep brain stimulation (DBS) has been established as a treatment strategy for medically refractory disease. 8, 34, 51, 55 Accepted targets of DBS for PD include the globus pallidus pars interna (GPi) and the subthalamic nucleus (STN). While STN stimulation may improve motor symptoms, 3 there are concerns regarding the worsening of axial symptoms and adverse behavioral/neuropsychiatric outcomes. 4, 22, 46, 48 Stimulation of GPi can lead to motor outcomes equivalent to STN stimulation, although there are concerns that this benefit may not be as sustained. 2, 11, 13, 18, 52 Thus, given the conflicting evidence and the lack of a comprehensive review comparing the 2 targets over a long term follow-up, a systematic review and meta-analysis is warranted.
Three systematic reviews on this topic have been conducted previously. 21, 40, 50 Based on primarily observational studies, Weaver and colleagues 50 concluded that STN was superior to GPi for medication reduction. Focusing on randomized-controlled trials (RCTs) only, Sako et al. 40 found a benefit in favor of GPi stimulation for depression. Liu et al. 21 found GPi to be superior regarding depression, while STN was superior for medication reduction. For these last 2 reviews, the inclusion of additional pertinent RCTs would have strengthened the evidence. 5, 29, 33, 36, 38, 45, 52, 57 Despite the contribution of these studies, there are currently no published reviews that have assessed RCTs with pooled outcomes beyond 12 months of follow-up. In addition, interpretation of results based on a formal evaluation of the quality of evidence (using the GRADE [Grading of Recommendations Assessment, Development and Evaluation] approach) has not been conducted.
14 Therefore, our objective was to conduct a comprehensive systematic review of RCTs comparing the 2 targets. We have sought to analyze a broader set of outcomes and adverse events (AEs), based on the inclusion of additional studies, along with addressing the aforementioned methodological factors. Outcomes have been assessed overall and separately, according to duration of follow-up.
Methods

Search Strategy
The MEDLINE (PubMed/Ovid), Embase, CEN-TRAL, and Web of Science electronic databases were searched on January 14, 2015. MeSH terms/keywords related to DBS and PD were used. This was supplemented by a search of the bibliographies of included studies and manually screening the tables of contents (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) of Movement Disorders, Neurology, Archives of Neurology, Annals of Neurology, Stereotactic and Functional Neurosurgery, Journal of Neurosurgery, and Neurosurgery. ClinicalTrials.gov and BioMed Central were also searched to identify upcoming trials. Another search of MEDLINE and Embase was conducted on April 14, 2015 , to identify additional publications.
Search Terms
Our strategy was developed separately for each database, based on terms pertaining to primary PD, DBS, and RCTs as study methodology.
Study Selection
Title/Abstract Screening and Full-Text Review
All identified references and retrieved full-text articles were reviewed for eligibility, independently and in duplicate (A.M. and S.T.). Kappa scores were calculated to measure agreement. Studies were included if they were based on adults (age ≥ 18 years) with idiopathic PD and DBS was used as an intervention, with outcomes for each target reported. Neither date nor language was a limitation.
Data Collection
Data from selected studies were abstracted independently (by A.M. and S.T.), and the accuracy was verified by a third author (J.H.B.). Study characteristics were collected independently and in duplicate (by C.D.W. and F.N.).
Outcomes
The primary outcomes were ranked by the panel of senior authors. United Parkinson's Disease Rating Scale (UPDRS) III score and change in levodopa-equivalent dose (LED) were deemed "critical" and UPDRS II score was of "high" importance, while neuropsychological impact and procedure-related AEs were judged to be of "moderate" importance. The major AEs sought included dysphagia, dysarthria/speech problems, and axial symptoms (e.g., gait, balance, and postural disturbances). Axial symptoms are established debilitating symptoms associated with PD, and the response of each patient to DBS is not uniform. 10 For AEs of varying reported severity, the component with the largest number of events was considered.
Quality Assessment of Individual Studies
Two investigators (A.M. and S.T.) independently performed quality assessment, using the Cochrane Collaboration's tool. 16 Studies with unexplained deviations from prior protocols/methods and lacking an adequate description of conflicts of interest/sources of funding were judged to have a high risk of "other bias." We judged trials with ≥ 2 and ≥ 4 high-risk components as moderate risk and high risk, respectively. Sensitivity analyses were conducted to determine the impact of studies with moderate/high risk of bias.
Overall Quality Assessment of Evidence Grade
The GRADE guidelines were applied to eligible studies by 2 independent authors (A.M. and S.T.), using GRADEPro software (version 3.6.1; The Cochrane Collaboration).
Statistical Analysis
Weighted mean differences (WMDs) or risk ratios (RR) with associated 95% confidence intervals were calculated for continuous and dichotomous outcomes, respectively. Final mean values were preferred. In cases where only a percentage change in mean value was reported, the final value was calculated by subtracting the relative change from the baseline mean values. Pooled summary statistics were calculated using a fixed/random effects (inverse variance) model, depending on the heterogeneity. In cases of values reported as medians (and interquartile ranges [IQRs] ), assumptions regarding the normality of distribution were made to obtain the SD through dividing the IQR by 1.35. 16 A sensitivity analysis was conducted to assess the robustness of estimates based on this assumption. Between-study heterogeneity was measured by the I 2 statistic, with values exceeding 75% representing high heterogeneity. 17 Duration of PD and proportion of enrolled males were assessed through subgroup analyses, as described below. Review Manager (v5.3; The Cochrane Collaboration) was used for all other statistical analyses.
Duration of PD (a priori)
Disease duration can have an impact on response to DBS. 42, 54 The threshold for categorizing studies as short or long PD duration in our analysis was arbitrary and based on a comparison of baseline parameters across studies; studies with an average PD duration > 12 years were categorized as "long duration."
Proportion of Enrolled Males (post hoc)
The differential impact of the proportion of enrolled male patients was assessed by comparing outcomes from trials with > 80% males to those with < 80% males. This was an arbitrarily selected threshold, but it was based on the range of proportion of males in included studies (66%-87%). 
Results
General Study Characteristics
Thirteen studies (6 original trial cohorts) were identified ( Tables 1-3 . Studies excluded from the quantitative meta-analysis have also been listed in Table 2 , along with reasons for exclusion. 27, 28, 44, 53 An almost perfect agreement was noted for both the title/abstract screening (kappa 0.81, standard error [SE] 0.07; 95% CI 0.68-0.95) and the full-text review (kappa 0.89, SE 0.08; 95% CI 0.73-1).
The majority of trials were multicenter (8 publications, 2-13 centers), had an average patient age > 60 years, and had a large proportion of male participants (range 66%-87%). The duration of follow-up ranged from 6 to 36 months. Three trials were registered a priori. 11, 30, 32 Three had a moderate risk of bias, [36] [37] [38] while the remainder had a low risk of bias ( Supplementary Fig. 1 ).
Pooled Outcomes
The pooled outcomes are shown in Tables 4 and 5 . The GRADE Evidence Profile is shown in Supplementary  Table 1 .
Motor Symptoms On Medication
The GRADE quality of evidence for this outcome was moderate. Five trials reported UPDRS III scores (on medication); GPi stimulation resulted in a nonstatistically significant improvement 1, 29, 33, 36, 52 ( Fig. 2 ). Pooling reports with similar durations of follow-up did not yield significant differences.
Motor Symptoms Off Medication
The GRADE quality of evidence for this outcome was very low. Four original trials reported UPDRS III scores (off medication); 1, 29, 33, 52 STN stimulation resulted in a nonsignificant improvement (Fig. 3) . A sensitivity analysis excluding the CSP-VA trial (Weaver et al. 52 ), due to noticeable variation of mean differences, led to a significant pooled estimate in favor of STN (Table 4) : WMD -4.58 (95% CI -8.71 to -0.44), p = 0.03. Pooling of studies with similar duration of follow-up suggested an initial benefit in favor of GPi at 6 months but at 12 months a benefit was seen in favor of STN. Subsequently, however, no significant differences were noted. Studies enrolling < 80% male patients resulted in a significant benefit in favor of STN; this analysis excluded 1 study, which also had the highest proportion of patients lost to follow-up. 52 
Medication Reduction
The GRADE quality of evidence for this outcome was high. Five original trials reported on LED reduction 5, 29, 33, 36, 52 ; STN stimulation resulted in a significant benefit (Fig. 4) : WMD -365.46 (95% CI -599.48 to -131.44), p = 0.002, I 2 = 58%. Based on the 2 studies with > 80% males, 36, 52 the stimulation of STN did not result in a significant benefit.
Activities of Daily Living On Medication
The GRADE quality of evidence for activities of daily living outcome was moderate. Three original trials reported UPDRS II scores (on medication); 1, 29, 52 GPi stimulation resulted in a nonsignificant benefit (Fig. 5) . 
Quality of Life
Three studies reported on quality of life. 11, 30, 57 In the NSTAPS trial, the PDQL (Parkinson's Disease Quality of Life) scale was used, and no significant difference was noted. The COMPARE and VA-CSP trials used the PDQ-39 scale, and while the former showed significant improvements through GPi (38%) versus STN (14%), the latter showed no overall difference. Given the variation in scales used and the individualized reporting of scale items, overall quality of life data were not pooled.
Depression
Three original trials reported Beck Depression Inventory (BDI) scores, 11, 33, 38 suggesting an advantage in favor of GPi: WMD 2.53 (95% CI 0.99-4.06), p = 0.001, I 2 = 0%. A significant difference was noted in patients undergoing GPi stimulation with respect to continuous but not categorical variables (Tables 4 and 5 , respectively).
Adverse Events
Two trials reported on dyskinesias (Clinical Dyskine- (Table 4) .
Two studies reported on dysphagia, 1,29 and 3 reported on dysarthria/speech difficulties. 11, 30, 32 Pooling these results suggested a nonsignificant benefit in favor of GPi stimulation. Six studies reported outcomes pertinent to the assessment of axial symptoms. 1, 11, 29, 30, 44, 45 Only 2 studies were pooled quantitatively, due to similarities in UPDRS III subitems measured, and no significant overall differences were noted (Table 4 ). In the 24-month report of VA-CSP, 11 only severe falls were significantly higher in the STN cohort (8.8% vs 3.3%, p = 0.05). Assessing the sum of Items 29 and 30 of the UPDRS III scale, St George et al. 45 showed a postoperative benefit in favor of GPi (p = 0.048). Using the activities-specific balance confidence scale, the authors reported improvements in the postoperative outcomes in the GPi cohort (p = 0.05) only, compared with baseline.
Discussion
This meta-analysis is the first of its kind to include pooled outcome comparisons of RCTs based on PD patients undergoing STN vs GPI DBS for follow-up periods beyond 12 months. The 2 targets were comparable in terms of improvement of UPDRS II and III scores, whether on or off medication. Stimulation of STN led to a significant reduction of medication dosage, while GPi stimulation resulted in significantly better BDI scores. These findings were qualitatively similar to the 2 other systematic reviews of RCTs, 21, 40 suggesting that differences in outcomes through stimulation of either target carry forward to 36 months of follow-up. There was no significant difference in disabling dyskinesias, dysphagia, or dysarthria/speech across targets. The evidence regarding axial symptoms was contradictory. The only outcome with a high quality of evidence was medication dosage reduction. 
Motor Outcomes
Although the pooled summary of both studies with 36-month outcomes (on and off phases) showed no difference, the off-phase summary statistic was associated with a high degree of heterogeneity. 29, 52 This is likely attributable to the variable methodological approaches, with one study conducting stimulation setting and medication dosage adjustments in a blinded manner. This possibility is further strengthened by demonstration of a significant benefit in favor of the STN, through an exclusion of the CSP-VA trial, in our sensitivity analysis. In addition, the variation of pooled results between 6-month, 12-month, and 36-month data may be illustrative of regression toward the mean, further confirming the need for long-term follow-up.
In a post hoc subgroup analysis of studies in which less than 80% of patients were male, an improvement in off phase symptoms was noted in STN patients. Males have been shown to be susceptible to more severe PD, 15 while females undergoing STN stimulation are thought to be more susceptible to "brittle dyskinesias"; 43 therefore, exploration of the interaction of sex and target could be informative.
Medication Dosage Reductions
Stimulation of the STN enabled a greater reduction of medication. Studies of patients with a longer duration of PD 36, 45 or groups with a higher proportion of males 36, 45, 52 did not observe this benefit. Long-term medication therapy has been speculated to induce changes at the gene and cellular level, 6, 7 while the progressive degeneration of dopamine production is thought to lower the threshold for dyskinesias. 35 Therefore, in patients with advanced PD, it is possible that stimulation of either target may not compensate for the extensive neurodegeneration. Future RCTs examining the differential impact of these 2 parameters would be enlightening.
Depression
The advantage of GPi stimulation in terms of depression is qualitatively consistent with the findings of other studies. 11, 21, 39 The vicinity of the STN to structures with extensive connectivity with the limbic system 24 implies that slight variations in electrode placement within the STN could adversely affect mood symptoms. The rapid withdrawal of medication afforded by STN stimulation can also be a factor. Alternatively, it must be borne in mind that these conclusions are mainly driven by the single largest trial with data available on this outcome and additional studies would help strengthen conclusions.
Adverse Events
GPi stimulation resulted in a trend toward dyskinesia reduction in the on-medication phase. Therefore, patients with levodopa-induced dyskinesias in whom a reduction of medication cannot be attained (e.g., due to dopaminergic, drug-responsive mood symptoms) could benefit from GPi stimulation instead. 39 The progression of dysarthria and dysphagia can be influenced by DBS. This is particularly true with stimulation of the STN, due to its vicinity to corticobulbar pathways. 20, 39, 47 In our review, the reported rates of either outcome were similar across both targets. More robust methods of event documentation, supplemented with a comparison with presurgical patient status, are necessary.
The evidence regarding the correlation of axial symptoms and target site was conflicting. The between-study heterogeneity can be attributed to variations in study methodology, differences in choice of summative evaluation of the subcomponents of UPDRS III, or use of other scales altogether. Furthermore, although the 12-month data from the NSTAPS trial 30 favored the STN, this latter difference was not sustained at 36 months. 29 The within-study difference may be due to disease progression. In addition, gait and balance are a reflection of a complex interaction of PD-related symptoms with cortical, subcortical, and spinal pathways. 45 Ultimately, stimulation of either target may re- sult in similar overall outcomes, and specific patient-and stimulation-dependent parameters are contributory.
Implications for Practice
The current evidence points to the clear superiority of STN stimulation for reduction of medication. However, caution must be advised against aggressive medication reduction in light of the deterioration of nonmotor symptoms and the influence of these symptoms on quality of life.
41
The concurrent influence of the aging-associated cognitive decline and that observed in PD highlights the importance of conservative dosage reduction. The results of the RCT examining the 6-month neurocognitive outcomes of PD patients with mild cognitive impairment undergoing DBS will be informative (NCT01870518; clinicaltrials.gov).
Implications for Research
Inadvertent stimulation of undesired segments within the STN and GPi nuclei, or traversing other nuclei such as the caudate, 56 partly explains the adverse effects associated with DBS in PD patients. Therefore, accurate placement of electrodes is critical, 12 and the DBS experience and case volume history of physicians involved in the care of patients would presumably be a factor. 25, 31 The lack of a unified method of assessing this parameter prevented us from analyzing its influence; the literature can benefit from uniform reporting of this factor in future trials.
A priori and post hoc subgroup analyses suggested a potential influence of sex and duration of PD on some outcomes. Whether DBS should be offered at an earlier point in the disease process remains controversial, 19, 23, 42 and various parameters such as patient age and duration of PD must be considered in patient selection. 9, 49 Future trials can more closely examine the role of these variables.
Limitations
This review was limited by the small number of studies, the nonuniform reporting of outcomes-particularly for AEs-and our various methodological assumptions. In addition, not all subgroups were based on a priori hypotheses, and arbitrary thresholds were used for comparisons. Nonetheless, this is the first review to report pooled estimate of outcomes at 36 months and to provide a summary of outcomes at varying time points of follow-up, based on a more comprehensive set of publications identified through our systematic search. Furthermore, outcomes were ranked by a panel with experience in DBS for PD and the overall quality of evidence was evaluated using the GRADE approach.
